NObreath®

$2,800.00$3,100.00

FeNO testing without limits

Play Video
Watch Video

Key Features and Benefits:

  • SIMPLE TEST – Non-invasive simple breath test
  • INSTANT RESULTS – Results appear instantly
  • NO LIMITS – Unlimited uses*
  • COST EFFECTIVE – Low-cost consumables.  Single-patient use mouthpieces can be used to repeat the test for the same patient in the same day visit up to 3 times
  • ADULT & CHILD MODES – 2 modes for best sampling times and quick results
  • EASY TO USE – Simple exhale-only technique and on screen visual motivation
  • PORTABLE – handheld design with 8 hour battery or 100 test life per battery charge

Ready to purchase, make your choice below or continue reading to learn more.

NObreath® Purchase Options:

Clear
SKU: NOBREATH Category:

Description

NObreath®

FeNO testing without limits

ONE BREATH AT A TIME

10 years of NObreath logo 2

The NObreath® has been a proven technology for over ten years of clinical use in studies worldwide.

The NObreath® is a FeNO (fractional exhaled nitric oxide) monitor which can be used to measure airway inflammation for the management and diagnosis of asthma. The NObreath® makes FeNO monitoring, which is recommended by The American Thoracic Society (ATS), quick and easy plus it is completely non-invasive, with the ability to monitor airway inflammation in both adult and child patients. Furthermore, the ambient monitoring mode enables you to check ambient levels of NO (nitric oxide).

fda logo

Key Features

  • null
    No Testing Limits
    Perform test after test with
    no limits on how many
    tests you can perform.*
  • null
    Cost Effective
    Low cost consumables. A
    patient can be tested up to
    3X in the same day using
    the same mouthpiece
  • null
    Easy to Use
    Non-invasive, quick and easy to perform
  • null
    Low Maintenance
    Simple annual maintenance,
    monitor operates without
    breath test limits & sensor
    is specified to operate for 5 years*
  • null
    Proven Technology
    NOreath® has over 10 years of clinical use in studies worldwide
  • null
    Optimum Infection Control
    NObreath® monitor’s housing is
    integrated with SteriTouch®
    antimicrobial additives.
  • null
    Adult and Child Modes
    Adult & child patient modes for the best sampling times and quick result referrals.
  • null
    Patient Profiles
    Ability to store patient profiles, readings, and view a graph of results

NObreath® FeNOchart Software Beta

• Included with every monitor purchase at no additional fee
• GDPR Compliant
• Create, store, and manage patient profiles
• Adult and child breath tests with screen mirroring
• View results in graph format with the ability to create reports in PDF format
• Automatic software updates
• Ability to remotely update the firmware of your NObreath®
Download SoftwareSoftware User ManualPlay Video

Software Overview

NObreath® Technical Specifications

NO Tech Specs

NObreath® Videos

Introduction

What is FeNO?

What is the NObreath?

How to take a test on the NObreath

How to use the NObreath

NObreath demo mode

NObreath Patient Profiles

Charging the NObreath

What is FeNO?

FeNO (fractional exhaled nitric oxide) are very miniscule particles of the gas nitric oxide (NO), measured in parts per billion. NO is naturally produced by your body to help combat inflammation and when your airway is inflamed, NO is produced in the lungs and exhaled on the breath.

The production of nitric oxide is often found to be higher in inflammatory conditions such as asthma and therefore FeNO monitoring can be used for the detection and management of such conditions2.

Airway inflammation is a central process in asthma and other lung diseases1. Being able to detect eosinophilic airway inflammation and monitor a patient’s response to treatment is regarded as a gold standard in the management of respiratory diseases.

Nitric oxide measurement is not intended as a stand-alone method for diagnosis and should be used in conjunction with other evaluation methods and tests3. Using FeNO measurements to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine 4, but until now this has been an expensive test to deliver in everyday practice.

Asthma and FeNO

Benefits of FeNO Testing

  • Non-invasive, quick, and easy to perform4
  • Shows patient’s response to treatment, enabling the correct prescription of medication and safer/monitored adjustments
  • Aids in identifying patients who do/do not require on-going treatment5
  • Shows patient compliance
  • Shown to be superior to the majority of conventional tests of lung function, such as peak flow recording and spirometry4
  • Aids in differentiating between allergic (eosinophillic) and non-allergic asthma6
Adult patient with Nurse

FeNO in Asthma

Asthma is commonly referred to as an inflammatory disease which affects a person’s airways, leading to hyper-responsiveness, obstruction, mucus hyper-production, and airway wall remodeling9. Although airway eosinophilic inflammation is a key characteristic of asthma, very few methods are available for measuring airway eosinophilic inflammation.

A majority of asthma patient’s airway inflammation is allergen driven Th2 response10. There is significant evidence from external literature suggesting FeNO (Nitric oxide) is a key biomarker tool for inflammation of the respiratory tract10. Increased levels of FeNO in asthma are thought to come from inducible NOS2 expressed in the inflamed airways10. The use of FeNO during asthma diagnosis and management, gives clinicians a more complete picture, helping them with key treatment decisions for asthma patients.  The American Thoracic Society recommends the use of FeNO in addition to usual care for patients that are being considered for the treatment of asthma11.  Please refer to the ATS website for the most up to date clinical practice guidelines on FeNO.  Literature also suggests the ability for FeNO measurement to be used as good management tool for asthma12, assessing the effectiveness of treatments for patients, optimizing asthma treatments.

The Cost of Asthma

USA logoUSA: According to Asthma and Allergy Foundation of America (aafa), approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8 percent of adults and 7 percent of children.13 It is the leading chronic disease in children.14 Currently, there are about 5.1 million children under the age of 18 with asthma.13 On average, ten Americans die from asthma each day. In 2019, 3,524 people died from asthma. Many of these deaths are avoidable with proper treatment and care.15 From 2008-2013, the annual economic cost of asthma was more than $81.9 billion – including medical costs and loss of work and school days: 16

  • $3 billion in losses due to missed work and school days
  • $29 billion due to asthma-related mortality, and
  • $50.3 billion in medical costs

UK logoUK: According to asthma UK, approximately 5.4 million people in the UK, receive treatment for asthma 8, and approximately 300 million individuals worldwide are thought to be affected by asthma9. It is thought that on average, 3 people die daily from asthma attacks in the UK.8 It is thought that the NHS spends approximately £1 billion a year treating and managing asthma symptoms 8.

Simple Testing Process

Conducting a breath test is simple, non-invasive, and instant.

1

Inhale and take a deep breath

2

Exhale gently into the mouthpiece

3

Follow onscreen prompts for exhalation

4

Instant reading in ppb NO

5

Explain Results

Inhale
Exhale 1
Exhale Follow Prompts
Result 1
Explain Results 1

NObreath® Infection Control

NObreath MP 1
Model holding Nobreath copy

NObreath® Mouthpiece Filtration Technology

The 2nd generation NObreath® Mouthpiece has an infection control filter, which has been tested vigorously by Public Health England to prove it removes and trap >99% and >98% of airborne bacteria and viruses respectively17.

The NObreath® mouthpiece has been tested to filter viruses as  small as 23 nanometers in diameter and the COVID-19 virus particle has an approximate diameter of approximately 125 nanometres18 . Due to the risky nature of testing live respiratory viruses, a non-pathogenic virus model is used (M2-Coliphage). The filters undergo both bacterial filter efficiency (BFE) and viral filtration efficiency (VFE). The virus model is incredibly penetrable, even more so than a majority of human viruses, therefore makes it a very affective model to use for virus filtration efficiency (VFE) testing. The model virus is approximately 24-26 nanometers in size17 in comparison to COVID-19 virus which is approximately 125 nanometers in size 18. Therefore, Bedfont® can conclude that bacterial and viral pathogens (including COVID-19) will effectively be removed by both the NObreath® mouthpiece filter at an efficiency rate of >99% (Bacteria) and >98% (viruses)17.

The NObreath® Mouthpiece is a single-patient use mouthpiece, meaning it should be disposed of according to local waste guidelines immediately after testing to further minimize the risk of cross infection.

Furthermore, when taking a FeNO measurement with the NObreath®, due to our uniquely designed NO scrubber and software algorithms, the patient does not inhale through the device or mouthpiece before exhaling, to reduce the risk of cross-infection.

Additionally, the NObreath® Mouthpiece is individually wrapped to aid in handling and the highest infection control.

NObreath SteriTouch New

SteriTouch®

We are proud to say the NObreath® monitor is integrated with SteriTouch® antimicrobial additives, which eradicate the bacteria that cause contamination and infection. SteriTouch® has released a statement on COVID-19 which reads, “Several of the active substances used by SteriTouch® have been successfully tested against other enveloped viruses, such as Influenza, Avian flu and SARS. It would be reasonable to imply that those same active substances would be effective against COVID-19, but at this stage testing against COVID-19 is not available19.”

Why NObreath®?

The most features and benefits for your money.

Model holding Nobreath hand

10 years of NObreath logo

10+ Year Heritage:

  • NObreath® has over 10+ years of clinical use in studies worldwide
  • FDA cleared

unlimited

No Limits:

  • Unlimited use*

Hour Glass

Save Time:

  • Instant boot up < 60 seconds
  • Breath test takes seconds – 12 seconds for adults and 10 seconds for children

cost effective nobreath

Low Operating & Maintenance Costs:

  • Inexpensive accessories
  • Simple calibration checks to ensure accurate readings

Touch

Simple User Interface:

  • Simple to use, large color LCD touch screen
  • Intuitive menus with icons
  • Onscreen flow meter will guide the patient on the exhalation rate

Customer Service

Training, Support & Service:

  • Online training included
  • Lifetime telephone technical support
  • All services & support handled in USA

Instant

Instant Results:

  • Non-invasive & quick breath test
  • Individual ppb NO in lungs
  • Ability to measure ambient NO

Adult and child profiles

Adult and Child Modes:

  • Adult & child patient modes for the best sampling times and quick result referrals

charts

Patient Profiles:

  • Ability to store 50 patient profiles with 25 results, and view a graph of results
  • Pin protected results
  • Automatically stores the last 250 results

antibacterial

Highest Levels of Infection Control:

  • Built-in SteriTouch™ antimicrobial additives, which eradicate bacteria that cause contamination and infection
  • NObreath® mouthpieces used in conjunction with the monitor filter out > 99% of airborne bacteria and > 98% of viruses and any moisture from the patient’s breath
    • Individually wrapped single-patient use mouthpieces for low cost infection control can be used up to 3 times on the same patient in the same day visit

Alarms

Automatic Reminders:

  • Service date is approaching and due
  • Battery level

Software Updates

Beta Software Included:

  • Included with every monitor purchase at no additional fee
  • GDPR Compliant
  • View results in graph format with the ability to create reports in PDF format
  • Automatic software updates

Reimbursement

Do you bill insurances for medical services?

CPT Vertical33
20.54

AVERAGE REIMBURSEMENT FOR A
NObreath® BREATH FeNO Test

CPT Code: 95012 – Fractional Exhaled Nitric Oxide (FENO) measurement, is approved in the assessment of adult and pediatric beneficiaries with suspicion of asthma and for asthma management.

Contact us to learn more.

Ideal for the following industries

RESPIRATORY THERAPY

RESPIRATORY THERAPY

Pulmonologist

PULMONOLOGIST

Clinicians

CLINICIANS

Primary Care Physican F

PRIMARY CARE PHYSICIANS

PEDIATRICIANS

PEDIATRICIANS

ALLERGISTS

ALLERGISTS / IMMUNOLOGISTS

Researchers

RESEARCHERS

Scientific Literature

If you are interested in receiving supporting data, please contact us and we would be happy to search our literature archive.

heart
Contact Us

Frequently Asked Questions

What is FeNo ?

FeNO (fractional exhaled nitric oxide) are very miniscule particles of the gas nitric oxide (NO), measured in parts per billion. NO is naturally produced by your body to help combat inflammation and when your airway is inflamed, NO is produced in the lungs and exhaled on the breath.

The production of nitric oxide is often found to be higher in inflammatory conditions such as asthma and therefore FeNO monitoring can be used for the detection and management of such conditions2.

Airway inflammation is a central process in asthma and other lung diseases1. Being able to detect eosinophilic airway inflammation and monitor a patient’s response to treatment is regarded as a gold standard in the management of respiratory diseases.

Nitric oxide measurement is not intended as a stand-alone method for diagnosis and should be used in conjunction with other evaluation methods and tests3. Using FeNO measurements to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine 4, but until now this has been an expensive test to deliver in everyday practice.

What are the benefits of monitoring FeNO with the NObreath®?

  • Non-invasive, quick, and easy to perform4
  • Shows patient’s response to treatment, enabling the correct prescription of medication and safer/monitored adjustments
  • Aids in identifying patients who do/do not require on-going treatment5
  • Shows patient compliance
  • Shown to be superior to the majority of conventional tests of lung function, such as peak flow recording and spirometry4
  • Aids in differentiating between allergic (eosinophillic) and non-allergic asthma6.

What is the NObreath® Forum?

Included at no additional fee with the purchase of a NObreath®, you are eligible to become a member of the NObreath® forum – a place where you can seek answers, offer help or simply discuss FeNO techniques, findings and much more with other healthcare professionals from around the world. Contact us to learn more.

RECOMMENDED

NObreath® Accessories

REFERENCES

1. Shelhamer JH, Levine SJ, Wu T, Jacoby DB, Kaliner MA, Rennard SI. NIH conference: airway inflammation. Ann Intern Med 1995;123:288-304.
2. Saito J, Gibeon D, Macedo P, Menzies-Gow A, Bhavsar P, Chung K. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. 2017.
3. Correlation of Exhaled Nitric Oxide, Spirometry and Asthma Symptoms: Journal of Asthma: Vol 42, No 10 [Internet]. Tandfonline.com. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/abs/10.1080/02770900500371344
4. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
5. D R Taylor, MW Pinenburg, A D Smith and J C D Jongste. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-827.
6. Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
7. Public Health England. An Evaluation of Filtration Efficiencies Against Bacterial and Viral Aerosol Challenges. Salisbury: Public Health England; 2020
8. Asthma facts and statistics | Asthma UK [Internet]. Asthma UK. 2019 [cited 2 December 2019]. Available from: https://www.asthma.org.uk/about/media/facts-and-statistics/
9. Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. Frontiers in Microbiology. 2013;.
10. Keller A, Rodriguez D, Russo M. Nitric oxide paradox in asthma. Memórias do Instituto Oswaldo Cruz. 2005;100(suppl 1):19-23.
11. ATS Website [cited 11 January 2022]. Available from: https://www.thoracic.org/about/newsroom/press-releases/journal/2021/new-clinical-practice-guideline-on-fractional-exhaled-nitric-oxide-feno-to-help-guide-asthma-treatment.php
12. Ricciardolo F, Sorbello V, Ciprandi G. FeNO as biomarker for asthma phenotyping and management. Allergy and Asthma Proceedings. 2015;36(1):88-88.
13. Centers for Disease Control and Prevention. (2020). 2019 National Health Interview Survey data. U.S. Department of Health & Human Services. Retrieved from: https://www.cdc.gov/asthma/nhis/2019/data.htm
14. Ferrante, G., & La Grutta, S. (2018). The Burden of Pediatric Asthma. Frontiers in Pediatrics, 6. https://doi.org/10.3389/fped.2018.00186
15. National Center for Health Statistics. National Vital Statistics System: Mortality (1999-2018). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Retrieved from: https://wonder.cdc.gov/ucd-icd10.html
16. Nurmagambetov, T., Kuwahara, R., & Garbe, P. (2018). The Economic Burden of Asthma in the United States, 2008–2013. Annals of the American Thoracic Society, 15(3), 348–356. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201703-259OC
17. Berkeywaterkb.com. 2020. Is The MS2 – Fr Coliphage Still Known To Be A Good Indicator Of Virus Filtration? Do You Have Tests On Any Other Viruses? – Berkey Knowledge Base. [online] Available at: http://berkeywaterkb.com/is-the-ms2-fr-coliphage-stillknown-to-be-a-good-indicator-of-virus-filtration-at-least-one-article-suggests-that-it-might-not-be-do-you-have-tests-on-any-other-viruses/ [Accessed 12 June 2020].
18. Avon-protection.com. 2020. [online] Available at: https://www.avon-protection.com/downloads/product_brochures/GR04471-01%20Coronavirus%20-%20WHITE%20PAPER.pdf [Accessed 12 June 2020].
19. SteriTouch. 2020. CORONAVIRUS – THE STERITOUCH STANCE. [online] Available at: https://www.steritouch.com/portfolio-posts/coronavirus-steritouch-stance/ [Accessed 12 June 2020]
*The NObreath® has been validated for up to 29,000 tests when used as instructed and properly maintained and serviced. The number of tests can be periodically checked within the settings of the device; when 29,000 tests are reached a service is recommended. Contact coVita.

Additional information

Weight 5 lbs
Dimensions 15 × 10 × 6 in
NObreath®

Monitor Only, Package